New

Oxaphil

The AI engine Fit Assessment

Beta

The company will attend Deep Tech Momentum 2026

Blurb

Manufacturer of poly(2-oxazoline)s (POx) intended to solubilize water-insoluble substances. The company develops and produces POx, serving the pharmaceutical and various other industries. Their products offer unique properties that enhance formulation stability and bioavailability, making them valuable for a range of applications.

HQ Location

Dresden (Germany)

Founded

2025

Employees

1 - 10

Total funding raised

Not available

Funding Status

Not available

We develop functional high-performance materials based on poly(2-oxazoline)s (POx): precise, scalable and biocompatible. Our focus is on manufacturing and applying next-generation solubilizers for active ingredients, cosmetic actives and other demanding formulations.

POx are versatile materials: they solubilize, stabilize, protect and enable controlled release. Their modular chemistry allows us to design custom-tailored solutions for real formulation challenges, often with superior precision and performance compared to conventional alternatives.

Our technology is built on a patented synthesis platform that enables us to produce POx in defined structure, high purity and scalable quantities. This makes a powerful class of materials accessible for industrial use – materials that have long been established in academic research but were rarely available commercially.

Oxaphil combines deep scientific expertise with a clear application focus. Our team brings together backgrounds in polymer chemistry, formulation science and technology transfer. In collaboration with partners, we translate POx from the lab to real-world applications from cosmetics to biotechnology and pharmaceuticals.